April 1, SZBL Pingshan Translational Medicine Center (PTMC) Deputy Director LI Zigang led a delegation to visit CR SANJIU and was welcomed by WANG Yong, Director of the Institute of Innovative Drug Discovery and relevant officials of CR SANJIU. The two parties joined a meeting that shared views on program developments as well as management experiences, before proceeding to discussion on biomedical collaboration regarding QBH-196, a targeting cancer-fighting drug. During the meeting, CR SANJIU R&D department delivered a briefing on QBH-196, covering the research progress, drug preparation, non-clinical and clinical treatment, CRO biding and so forth. The two parties discussed and compared notes on the organizing, project pipeline, clinical research protocol, project funding, task allocation and sharing of equity as part of the future collaboration.